A study concept described as “genetic barcodes” highlights how tumor biopsies can fail to capture the full clonal landscape of breast cancer, given tumors’ patchwork of competing cell populations. The approach is presented as a way to map what standard sampling misses—clones with different growth behavior, therapy resistance potential, and metastatic capacity. For oncology development, the work underlines a practical limitation in biomarker discovery and response prediction: if biopsy sampling undersamples rare resistant clones, clinical correlations may be misleading. The takeaway for translational teams is tighter requirements for sampling strategies, multi-region profiling, and interpretability of “missing clone” risk when using biopsy-derived datasets.